Navigation Links
Sensus Healthcare Awarded Sole Contract for Superficial Radiotherapy
Date:4/26/2011

BOCA RATON, Fla., April 26, 2011 /PRNewswire/ -- The Premier healthcare alliance, a network of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites working together to achieve high quality, cost-effective care, has awarded Sensus Healthcare, Inc., the leading provider of FDA-approved Superficial Radiotherapy committed to providing a viable treatment option for millions of skin cancer sufferers, a group purchasing agreement for the SRT-100™. Sensus was awarded a sole three-year contract for Superficial Radiotherapy with Premier Purchasing Partners L.P., the group purchasing unit of Premier, Inc. The agreement, which is in effect through April 1, 2014 extends Premier members preferred pricing on Sensus' Superficial Radiotherapy systems for treatment of basal cell and squamous cell carcinoma skin cancers.

(Logo: http://photos.prnewswire.com/prnh/20110124/FL34943LOGO)

"We are extremely pleased to partner with such a prestigious organization such as Premier and their members. We look forward to working with their healthcare professionals in establishing the SRT-100™ as the preferred choice for non-invasive skin cancer treatment," says Joe Sardano, CEO of Sensus Healthcare.

"According to experts, 50% of the booming 60+ population will be diagnosed with skin cancer. It's important for both physicians and patients to have choices for treatment. Surgery is simply not the best alternative for every patient these days," added Steve Cohen, VP Strategic Initiatives at Sensus Healthcare. "Much of our population has existing medical conditions that are better served by treating with non-invasive Photon X-Ray Therapy."

Over 2.8 million new skin cancer cases are diagnosed annually worldwide! Available for treatment of basal cell and squamous cell carcinomas, the SRT-100™ treats skin cancers, especially those requiring difficult or extensive surgery in sensitive areas of the head and neck regions - the fold in the nose, eyelids, lips, corner of the mouth, and the lining of the ear - that would otherwise lead to a less than desirable cosmetic outcome without the use of anesthetics or skin grafting.

The newly redesigned SRT-100™ offers improved mobility features and a streamlined look to simplify the non-melanoma treatment process while bringing safe, painless and effective skin cancer treatment to patients, right in the physician office. The SRT-100™ is powered with a standard electrical outlet and offers an easy, automated set-up procedure.

It is the only system of its kind available in the U.S. to treat non-melanoma skin cancers, and is now in use worldwide. SRT is a low energy radiotherapy that goes no deeper than the thickness of the skin. It is a proven non-invasive procedure that has been used to treat over 6,000 non-melanoma skin cancer patients in over 50 locations worldwide, and is highly recognized and reimbursable. Because the superficial x-rays concentrate radiation dose on the skin surface, the treatment has several advantages over conventional linear accelerators and surgical procedures.

The SRT-100™ is the treatment of choice for those patients seeking a non-surgical treatment option for skin cancer. Sensus offers a viable alternative, one that uses safe and effective low-energy radiotherapy to treat non-melanoma skin cancers. Many skin cancer patients may not even know that they have treatment options beyond surgery, which can lead to scarring and infection. Part of the process is educating the public that there are other ways to treat certain types of skin cancer - particularly around the neck, face, and scalp where 80% of skin cancer cases develop.

About the Premier Healthcare Alliance, Malcolm Baldrige National Quality Award recipient:

Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 73,000-plus other healthcare sites using the power of collaboration to lead the transformation to high quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington.

About Sensus Healthcare:

Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. We also offer a professional skin care line, Sensus Skin Solutions™, through our physician SRT-100™ users for their patients.

Contact:
Vicky Perez
Public Relations
561-922-5808 Ext 108
vicky@sensushealthcare.com


'/>"/>
SOURCE Sensus Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
2. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
3. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
4. TOPEX Sells Skin Cancer Business Operations to SENSUS Healthcare
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. ViroPharma to Present at Three Upcoming Healthcare Conferences
8. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
9. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
10. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
11. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/22/2017)... AVACEN Medical (AVACEN) announced that its CE-Marked ... those with the widespread pain associated with fibromyalgia in ... Essex, England commented, "I had ... no sleep at all, tremendous pain, with every movement ... [the AVACEN 100] enough, how this has and is ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:9/25/2017)... California (PRWEB) , ... September 25, 2017 , ... ... to announce the launch of its new website. No need to be ... has the answer. Go to welldonedesigns.com where all orders are printed and shipped ...
(Date:9/25/2017)... ... September 25, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that two of its ... of bioassays at two upcoming conferences. , At the BEBPA 10th Annual Bioassay ...
(Date:9/25/2017)... ... ... NCPDP Foundation , a 501(c)(3) nonprofit charitable organization ... grant to Johns Hopkins Medicine to address patient safety risk by implementing CancelRx ... a prescription already submitted to a pharmacy. Studies indicate that up to 3% ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... and efficiency. The principle of First-Defect-Stop for laboratory weighing is designed ... have the chance to have negative consequences on downstream processes. , If a ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... science and technology-enabled services supporting clinical research, today announces that 30 of ... aspects of the drug development lifecycle at upcoming industry conferences and webinars. ...
Breaking Medicine News(10 mins):